And elevating an interesting ICER gene therapy review that is flying below the radar
And almost everyone you can imagine just filed amicus briefs in the Merck IRA case
Plus lots of lots of polling that underscores why "Medicare negotiations" will be the "lockbox" of 2024
Plus a lawsuit story worth your time and a Regeneron quote to ponder
And a quick roundup of all the IRA legal news that seems to be falling between the cracks
Plus Roche's annual framing of their drug-price approach
And a ridiculous argument that making pro-innovation claims is 'bullying'
And the insulin price-cap debate remains mired in the congressional mud
And STAT's attempt to survey pharma about IRA highlights a huge catch-22 for industry
Plus an effort to dismantle -- or at least rethink -- today's high-profile NYT op-ed
Plus some thinking about reputation, and lots and lots of other news
And an answer on the Stelera IRA-list mystery
